AOP Orphan Pharmaceuticals GMBH v. Pharmaessentia USA Corporation
Case Number:
1:22-mc-91022
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
February 16, 2022
Austrian Pharma Co.'s €142M Award Nixed In Germany
A German court has set aside a €142 million ($161.8 million) damages award issued to Austrian pharmaceutical company AOP Orphan in the midst of a contentious dispute with Taiwanese drug developer PharmaEssentia Corp. over an ill-fated deal to develop a new blood cancer treatment.
-
January 20, 2022
AOP Orphan Accuses PharmaEssentia Of Arbitration Fraud
AOP Orphan has asked authorities in Germany to investigate allegedly deceptive statements a Taiwanese drug developer made during arbitration over an ill-fated deal to develop a new blood cancer treatment, including a proceeding in which the Austrian pharmaceutical company was awarded €140 million.